



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	Anti-HIV-1 p24 Monoclonal (71-31)
<b>Catalog Number:</b>	530
<b>Lot Number:</b>	160107
<b>Release Category:</b>	E
<b>Provided:</b>	100 µg of purified antibody at 2.0 µg/µL in PBS
<b>Description:</b>	A monoclonal antibody to HIV-1 p24
<b>Host:</b>	Human
<b>Titer:</b>	The user should determine the optimal concentration for any application.
<b>Special Characteristics:</b>	<p>This antibody was produced in cell culture and purified by Protein A/G chromatography. It originates from a hybridoma created by fusing EBV-immortalized B-cells from HIV-seropositive individuals and heteromyeloma SHM-D33 cells. Please see the <a href="#">LANL HIV Molecular Database</a> for more information.</p> <p>This antibody reacts with HIV lysate in ELISA. It reacts with the p55 core precursor as well as p24 and several intermediates as determined by Western blot. The antibody stains the cytoplasm of HIV infected cell lines.</p>
<b>Recommended Storage:</b>	Keep the reagent at 4°C for short term storage and at -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.
<b>Contributor:</b>	Dr. Susan Zolla-Pazner
<b>Isotype:</b>	IgG <sub>1</sub> λ

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**References:**

Gorny, M. K., Gianakakos, V., Sharpe, S., & Zolla-Pazner, S. (1989). Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A, 86(5), 1624-1628. [PUBMED](#)

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 p24 Monoclonal (71-31) from Dr. Susan Zolla-Pazner." Also include the reference cited above in any publications.

Patent pending. Corporate requests should be directed in writing to Dr. Susan Zolla-Pazner at the Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1090, New York, NY 10029.

**Recipient must not use or incorporate the reagent for commercial purposes.**

**Last Updated**

July 20, 2018

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.